Lawyers and Settlements
HOME CURRENT LEGAL TOPICS LEGAL NEWS POTENTIAL LAWSUITS LAWSUITS FILED SETTLEMENTS STATE LAW BLOG
Advertisement
Share this: 
Home Page >> Settlements >> Mylan to Pay $465M Over EpiPen Fraud

Mylan to Pay $465M Over EpiPen Fraud


This is a settlement for the lawsuit.

Santa Clara, CA: Mylan has agreed to pay $465 million to settle fraud claims that it underpaid rebates for the EpiPen, which amounts to stealing from the government federal authorities claimed. The lawsuit, alleging violations of the False Claims Act, was possible due to Sanofi acting as a whistleblower by alerting the federal government to the scam.

According to the terms of the now finalized agreement, Sanofi will receive $38.7 million for its role in alerting the government, together with a share of monies the states will receive as part of the financial recovery by state and federal health programs.

The lawsuit stemmed from Mylan’s deliberate misclassification of the EpiPen as being generic, which meant it paid lower rebates to the government than it should have. According to government regulations, drugmakers must pay Medicaid in the form of rebates to avoid price gouging. Further, drugmakers must pay a higher rebate to the government for drugs that are only available through a single source, which would be the difference between the current price and the price the drug would have cost if it had only increased by the rate of inflation. In 2009, an EpiPen two pack, which contains live saving medication used to treat people who are going into anaphylactic shock, a potentially fatal allergic reaction, rose in price by $500, from $100 to $600.

Sanofi became aware of Mylan’s alleged The False Claims Act rebate violations when it was allegedly developing its own version of an epinephrine injector, Auvi-Q. Sanofi claimed Mylan tried to block its Auvi-Q by forcing insurance companies to not cover it or to put it at a disadvantage on drug formularies.

Mylan did not admit liability in the settlement.

The case is United States ex rel Sanofi-Aventis US v. Mylan Inc. et al, case number 16-cv-11572, in the U.S. District Court for the District of Massachusetts.

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please fill in our form.
Please click here for a free evaluation of your claim

Published on Aug-17-17

Lawyers click here to submit your settlements and verdicts to have them published for free on our websites

READ MORE [ Consumer Fraud Settlements and Legal News ]
READ MORE [ Drugs/Medical Settlements and Legal News ]
READ MORE [ Whistleblower Settlements and Legal News ]

ADD YOUR COMMENT ON THIS ISSUE

Fields marked * are mandatory. Please read our comment guidelines before posting.

*Name:

Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.

*Your Comment:

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.
Share this: 
Request Legal HelpCheck Claim StatusAdvertise With UsLegal Funding Center
FAQ | TOS | Privacy | Disclaimer | About Us | Contact Us | Advertise

View Desktop Website

This work is licensed under a Creative Commons Attribution-NoDerivs 3.0 Unported License © 2001-2017 Online Legal Media. All rights reserved.